Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2024-02-21 Proxy Solicitation & In…
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated February 21, 2024, from Unichem Laboratories Limited. It contains detailed information about special business items to be approved by shareholders via postal ballot, including appointments of independent directors and approval of related party transactions. The document references the Companies Act, 2013, SEBI Listing Regulations, and voting procedures including e-voting. It is a notice sent to shareholders to seek their approval on specific resolutions, not the results of the voting or a report of the meeting. It is not an Annual Report, Earnings Release, or Management Report. It is also not a Declaration of Voting Results, as it precedes the voting period. The document is a formal notice for shareholder voting via postal ballot, which fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information and requests votes for the meeting resolutions.
2024-02-21 English
Intimation of Postal Ballot Notice
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated February 21, 2024, from Unichem Laboratories Limited. It contains detailed information about special business items to be approved by shareholders via postal ballot, including appointment of independent directors and approval of related party transactions. The document references relevant sections of the Companies Act, 2013, and SEBI Listing Regulations, and provides instructions for remote e-voting. It is a notice sent to shareholders to seek their approval on specific resolutions, not the results of voting or a report of the meeting. It is not an Annual Report, Board/Management change announcement, or voting results declaration. The content fits the category of Proxy Solicitation & Information Statement (PSI), as it is material sent to shareholders to provide information and request votes for a meeting via postal ballot.
2024-02-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding the completion of a USFDA inspection at the company's manufacturing facility. It is an intimation under SEBI Regulation 30, which pertains to disclosure of material events. The document does not contain financial data, audit results, or detailed reports. It is an announcement of a regulatory event related to compliance and inspection outcome. Given its brief nature and regulatory disclosure context, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-02-13 English
The United States Food and Drug Administration (USFDA) conducted inspection at the Company''s Ghaziabad (Uttar Pradesh) formulation facility from February 7, 2024 to February 13, 2024
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding the completion of a USFDA inspection at the company's manufacturing facility. It is an intimation under SEBI Regulation 30, which pertains to disclosure of material events. The document does not contain financial data, audit results, or detailed reports but is an announcement of a regulatory event. The length is only 1311 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-13 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial results for the third quarter and nine months ended December 31, 2023, including standalone and consolidated unaudited financial results with figures and notes. It mentions review by the Audit Committee and approval by the Board of Directors, as well as a limited review by statutory auditors. The document includes substantive financial data and analysis, not just an announcement or summary. The presence of quarterly and nine-month financial results with detailed figures and notes indicates this is an Interim / Quarterly Report. There are also other unrelated notices and legal announcements, but the primary financial content is the quarterly results. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2024-02-06 English
Financial Results for the third quarter and nine months ended December 31, 2023, for the financial year 2023-24, published in the newspaper on February 6, 2024.
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial results for the third quarter and nine months ended December 31, 2023, including standalone and consolidated unaudited financial results with figures and notes. It mentions review by the Audit Committee and approval by the Board of Directors, as well as a limited review by statutory auditors. The document includes comprehensive financial data and analysis for a period shorter than a full fiscal year (quarter and nine months). This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is the report itself, not just an announcement or certification. Therefore, the correct classification is IR with high confidence.
2024-02-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.